突发！600079，将被ST

Core Viewpoint - Humanwell Healthcare will be subjected to ST treatment due to false financial disclosures in its annual report, as indicated by the China Securities Regulatory Commission [2][4] Group 1: Financial Violations - The company failed to timely disclose non-operating fund occupation of 12.785 billion yuan from 2020 to 2022, with 2.502 billion yuan in 2020 accounting for 17.58% of net assets [5] - The 2020 annual report omitted the disclosure of 2.502 billion yuan in fund occupation (19.26% of net assets), and the 2022 annual report did not disclose 1.645 billion yuan in related party transactions [5] - The annual reports for 2020, 2021, and the first half of 2022 inflated net profits by 143 million yuan, 72 million yuan, and 91 million yuan respectively [5] Group 2: Penalties and Consequences - The total fines imposed amount to 36.7 million yuan, including 8.5 million yuan for Humanwell Healthcare, 9 million yuan for the controlling shareholder, and 3.9 million yuan each for the former chairman and the actual controller [5][6] - The actual controller, Ai Luming, is proposed to be banned from the market for seven years due to his central role in the violations [6] Group 3: Ownership Changes - The controlling shareholder changed to China Merchants Biomedical in July 2025, ending the 32-year control by the "Contemporary System" [8] - Following the change in control, there was a significant turnover in the executive team, with multiple resignations attributed to "personal reasons" [8][9] Group 4: Financial Performance - The company's net profit declined from 2.484 billion yuan in 2022 to 1.33 billion yuan in 2024, nearly halving [10] - In the first three quarters of 2025, Humanwell Healthcare reported revenue of 17.883 billion yuan, a year-on-year decrease of 6.58%, while net profit attributable to shareholders increased by 6.22% to 1.689 billion yuan [12] - The company has received approval for 10 new drugs this year, indicating a focus on innovation [12]